Drawing for UZEDY

USPTO serial 79456733

UZEDY

Reviewed by CopyMark Law Group

Status 640Office Action
Filing date
Status date
Registration date
—
Examiner
LAVOIE, RYAN CHRISTOPHER
Law office
TMEG LAW OFFICE 108

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Status 640: Status 640 means the examining attorney has prepared a non-final Office Action but it has not been mailed or e-mailed yet. The action should appear in TSDR soon, and a response deadline will start once it is issued.

Need help with UZEDY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the prevention and treatment of alzheimer's disease; pharmaceutical preparations for the prevention and treatment of depression; pharmaceutical preparations for the prevention and treatment of psychological disorders; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of osteoporosis; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of sexual dysfunction; pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; pharmaceutical preparations for the prevention and treatment of aids-related disorders; pharmaceutical preparations that support, encourage and promote bone strength; pharmaceutical preparations that support, encourage and promote bone health; pharmaceutical preparations used in the treatment of bone disorders and bone diseases; pharmaceutical preparations, namely, injectable contraceptives; pharmaceutical preparations, namely, contraceptive preparations; pharmaceutical preparations, namely, fertility enhancement preparations; pharmaceutical preparations, namely, hormone replacement therapy preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical agents affecting the central nervous system; pharmaceutical agents affecting circulatory systems; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting urogenital organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for the treatment of neurological disorders.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 26, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 25, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 21, 2026DOCKASSIGNED TO EXAMINER—
Aug 24, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 24, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 20, 2026REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance